WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...
A Chinese pharmaceutical company expects to hire up to 500 employees for the first phase of its new campus in northern ...
At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...
CMB International Securities analyst Jill Wu has maintained their bullish stance on WXIBF stock, giving a Buy rating on January 13.Stay Ahead ...
WuXi Biologics differentiates itself from other well-established global contract development and manufacturing organizations, with its "follow-and-win the molecule" and "global dual-sourcing ...
Then on Jan. 6, affiliated company WuXi Biologics said its subsidiary WuXi Vaccines plans to sell its vaccine plant in ...
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
NEW DELHI: India is bracing for possible disruptions to its pharmaceutical industry - where the American market accounts for ...
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: The Biopharmaceutical Contract ...